anti-tumor efficacy
Tumor-specific activated photodynamic therapy with an oxidation-regulated strategy for enhancing anti-tumor efficacy
... vitro anti-tumor efficacy of HA-GA@Ce6 was anticipated to efficiently suppress tumor ...superior tumor accumulation in vivo, we further evaluated the anti-tumor ...
13
Trastuzumab anti tumor efficacy in patient derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models
... that anti-proliferative activity reflected the degree of HER-2 expression detected by flow cytometry, but not by HercepTest nor fluorescence in situ hybridization ...Trastuzumab anti-tumor ...
11
Superior anti-tumor efficacy of diisopropylamine dichloroacetate compared with dichloroacetate in a subcutaneous transplantation breast tumor model
... breast tumor at the same dose after 24 days ...of tumor tissue in a mouse subcutaneous transplantation breast tumor ...better anti-tumor efficacy than DCA in a breast cancer ...
11
Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide
... suppressed tumor growth initially, after 2 weeks of treatment, tumors no longer responded to treatments and grew ...the tumor cells developing drug resistance to ...in tumor growth rate after the ...
9
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
... with anti-PD-1 therapy; different studies suggest different species may be enriched in responding versus non-responding patients [30, ...to anti-PD-1 antibodies had higher levels of CD8 T-cell density in ...
11
<p>Tumor Targeting Chemo- and Photodynamic Therapy Packaged in Albumin for Enhanced Anti-Tumor Efficacy</p>
... with tumor-targeting fusion protein ATF-HSA using strong hydrophobic drug paclitaxel (PTX) as a coupling agent for its af fi nity with HSA to form fi nal product ATF- HSA@HSA:mPPZ:DOX nanoparticles (abbreviated as ...
17
Propranolol potentiates the anti-angiogenic effects and anti- tumor efficacy of chemotherapy agents: implication in breast cancer treatment
... after tumor cell injection and consisted of ...and tumor size evaluation. B) Quantitative analysis of tumor growth by weekly measurements of luciferase activity in mice treated with saline only ...
13
<p>Anti-Tumor Efficacy of an Adjuvant Built-In Nanovaccine Based on Ubiquitinated Proteins from Tumor Cells</p>
... for Western blot analysis. All the samples were mixed with SDS-PAGE loading buffer (Invitrogen) and boiled for 5 mins. Then, the samples were centrifuged at 12000 g for 10 mins and the supernatant was resolved by 12.5% ...
15
Stimuli-Responsive Nanotheranostics for Real-Time Monitoring Drug Release by Photoacoustic Imaging
... understand tumor pathology and guide precision ...image tumor-specific biomarkers, limitations in their molecular structure hamper them from effective drug delivery and the drug release ...monitor ...
11
Formulation design, preparation, and in vitro and in vivo characterizations of β-Elemene- loaded nanostructured lipid carriers
... - tumor-bearing mice were used to assess whether β -E-NLCs exhibited higher anti-tumor ...of tumor weight and inhibition of H 22 in mice are shown in Figure ...the anti-tumor ...
9
Mitochondria Determine Response to Anti-PD-1 Therapy: An Evidence-based Hypothesis
... There are a bunch of TILs in the TME with various c-ATP levels due to different access to nutrients and different levels of encounter with cancer cells. Based on our hypothesis, this difference may result in the varied ...
9
Tumor specific delivery and therapy mediate by integrin β6- target immunoliposomes for β6-siRNA in colon carcinoma
... siRNA anti-tumor efficacy of β6- TLPs in vivo, β6-siRNA loaded in Lipo2000, NTLPs and TLPs at the dose of siRNA ...by tumor growth, was shown in Figure 6A and ...suppressed tumor growth ...
13
Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanoma
... non- tumor tissues is first released into the blood, then circu- lates to tumor tissue and exerts the antiangiogenesis ...increase anti-tumor efficacy, modification of vector or ...
11
Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies
... cell anti-tumor function ...KPC tumor cells. Tumor-bearing mice were treated with Cy, either Empty Lm or Lm-ANXA2, in context of either anti-PD-1 anti- body or IgG as described ...
13
Is CD47 an innate immune checkpoint for tumor evasion?
... cells, tumor-specific delivery of CD47 blockade would generate better anti-tumor effect with fewer side effects than sys- temic ...the tumor tissues specifically becomes the challenge. ...
7
Efficacy of limb salvage with primary tumor resection simultaneously for solitary bone metastasis in limbs
... Bone metastases are the most common first manifest- ation of lung cancer, kidney cancer, myeloma, and lymphoma. Although breast and prostate cancer are the most common primary sites of bone metastases, they rarely take ...
6
Tumor conditional anti CTLA4 uncouples antitumor efficacy from immunotherapy related toxicity
... the tumor-targeted conditional ...the tumor antigen PSCA, so a mouse PSCA-specific mAb (10E8 clone) was generated to target the tumor as the OD of the conditional DVD (herein referred to as ...
16
Analysis of the clinical efficacy of tumor resection methods used in 20 patients with clavicular tumor
... lar tumor and underwent intracapsular resection, suffered from local recurrence and had a re-operation 5 months ...follow-up. Tumor excision and radiotherapy were performed on patients 12 and ...
7
IN-VIVO ANTI-TUMOR EFFECT OF 5-FLUOROURACIL LOADED CHITOSAN-SODIUM DEOXYCHOLATE NANOPARTICLES
... chemotherapeutic agents into nanocarriers in recent years. [7] Previous reports indicated that sustained release formulations of 5-FU and selective delivery to the tumor site not only improve the antitumor ...
7
Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial
... were assessed every 6 weeks for the first year and every 12 weeks thereafter by investigators according to RECIST v1.1. Safety was assessed at each biweekly visit, and AEs were graded according to the National Cancer ...
9